Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Woods

Clinical Nurse Specialist Akron, OH Clinical Nurse Specialist

NPI 1801815170 CMS profile 11211597

701 White Pond Dr, Suite 300, Akron, OH 44320

Open in the dashboard

General payments

$19,326

1,013 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Woods of Akron, OH is reported in the CMS Open Payments database as having received $19,326 across 1,013 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Clinical Nurse Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,242 213
2024 General $4,901 213
2023 General $3,295 188
2022 General $3,845 227
2021 General $3,044 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Woods
  • Clinical Nurse Specialist median
  • Middle half of Clinical Nurse Specialist
  • National median

In program year 2025, general payments to Jennifer Woods were reported at $4,242. Among 490 Clinical Nurse Specialist profiles paid that year, the median was $149 and the middle half received between $61 and $470.

Show as a table
Year Jennifer Woods Clinical Nurse Specialist median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,044 $132 $42–$386 $132
2022 $3,845 $140 $55–$364 $149
2023 $3,295 $145 $50–$403 $160
2024 $4,901 $145 $55–$430 $164
2025 $4,242 $149 $61–$470 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alexion Pharmaceuticals, Inc. $1,711 49 payments
  2. AbbVie, Inc. $1,441 104 payments
  3. Biogen, Inc. $1,080 58 payments
  4. Novartis Pharmaceuticals Corporation $1,079 87 payments
  5. Jazz Pharmaceuticals Inc. $918 47 payments
  6. UCB, Inc. $867 37 payments
  7. Harmony Biosciences LLC $792 46 payments
  8. Genzyme Corporation $726 18 payments
  9. SK Life Science, Inc. $719 42 payments
  10. EMD Serono, Inc. $671 42 payments
  11. Other $9,323 483 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,626 998 payments
  2. Consulting Fee $1,220 5 payments
  3. Education $479 10 payments
Products named General payments · program years 2021–2025
  1. ULTOMIRIS $1,325 33 payments
  2. UBRELVY $1,095 77 payments
  3. QULIPTA $944 74 payments
  4. TYSABRI $904 53 payments
  5. XYWAV $657 28 payments
  6. KESIMPTA $649 59 payments
  7. Briviact $546 22 payments
  8. INGREZZA $517 33 payments
  9. ENTYVIO $501 26 payments
  10. AIMOVIG $494 25 payments
  11. Other $11,177 606 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

3,883

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$1,226,931

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

31%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 15 $178,404
Nuplazid Pimavanserin Tartrate Brand 16 $155,571
Xcopri Cenobamate Brand 90 $113,734
Wakix Pitolisant Hcl Brand 14 $103,146
Qulipta Atogepant Brand 69 $80,965
Nourianz Istradefylline Brand 28 $78,223
Epidiolex Cannabidiol (Cbd) Brand 11 $63,706
Briviact Brivaracetam Brand 36 $50,458
Fycompa Perampanel Brand 42 $49,057
Nurtec Odt Rimegepant Sulfate Brand 17 $30,293

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$15,399

Medicare's payments for the services billed

Medicare patients

214

Average age 73

Services billed

290

109 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 56%
Depression 35%
Diabetes 29%
Chronic kidney disease 29%
Ischemic heart disease 25%
Alzheimer's or dementia 19%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
$754 — —
WAKIX
$297 14 —
KESIMPTA
$227 — —
Sunosi
$206 19 —
Briviact
$195 36 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

1,013 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record